Skip to main content
300 Collins St Melbourne
hello@pivot.net
Login
Signup
Main navigation
About
Team
Contact
Research & Development
Innovation Engine
Therapeutic Focus
Development Strategy
Publications/Presentations
Pipeline
RMC-4630
Mutant RAS
SOS1
RMC-5552
Investors
Careers
Publications/Presentations
Publication / Presentation
April 29, 2020
Allosteric inhibition of SHP2 stimulates anti-tumor immunity by transforming the immunosuppressive environment
Read more
Publication / Presentation
February 26, 2020
Strategies to Inhibit RAS-Driven Cancers
Read more
Publication / Presentation
January 12, 2020
The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial.
Read more
Publication / Presentation
January 12, 2020
Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in preclinical models of NSCLC
Read more
Publication / Presentation
January 11, 2020
The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial.
Read more
